JP2015529655A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529655A5 JP2015529655A5 JP2015525554A JP2015525554A JP2015529655A5 JP 2015529655 A5 JP2015529655 A5 JP 2015529655A5 JP 2015525554 A JP2015525554 A JP 2015525554A JP 2015525554 A JP2015525554 A JP 2015525554A JP 2015529655 A5 JP2015529655 A5 JP 2015529655A5
- Authority
- JP
- Japan
- Prior art keywords
- registered trademark
- statin
- simvastatin
- subject
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261678992P | 2012-08-02 | 2012-08-02 | |
| US61/678,992 | 2012-08-02 | ||
| US201261695807P | 2012-08-31 | 2012-08-31 | |
| US201261695850P | 2012-08-31 | 2012-08-31 | |
| US61/695,850 | 2012-08-31 | ||
| US61/695,807 | 2012-08-31 | ||
| PCT/US2013/053007 WO2014022551A1 (en) | 2012-08-02 | 2013-07-31 | Methods for treatment of atherosclerosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017195835A Division JP2018012726A (ja) | 2012-08-02 | 2017-10-06 | アテローム性硬化症の処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015529655A JP2015529655A (ja) | 2015-10-08 |
| JP2015529655A5 true JP2015529655A5 (enExample) | 2016-09-15 |
Family
ID=50028503
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525555A Pending JP2015524439A (ja) | 2012-08-02 | 2013-07-31 | アテローム性硬化症の処置方法 |
| JP2015525554A Pending JP2015529655A (ja) | 2012-08-02 | 2013-07-31 | アテローム性硬化症の処置方法 |
| JP2017194137A Pending JP2018016637A (ja) | 2012-08-02 | 2017-10-04 | アテローム性硬化症の処置方法 |
| JP2017195835A Pending JP2018012726A (ja) | 2012-08-02 | 2017-10-06 | アテローム性硬化症の処置方法 |
| JP2019042213A Pending JP2019108389A (ja) | 2012-08-02 | 2019-03-08 | アテローム性硬化症の処置方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525555A Pending JP2015524439A (ja) | 2012-08-02 | 2013-07-31 | アテローム性硬化症の処置方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017194137A Pending JP2018016637A (ja) | 2012-08-02 | 2017-10-04 | アテローム性硬化症の処置方法 |
| JP2017195835A Pending JP2018012726A (ja) | 2012-08-02 | 2017-10-06 | アテローム性硬化症の処置方法 |
| JP2019042213A Pending JP2019108389A (ja) | 2012-08-02 | 2019-03-08 | アテローム性硬化症の処置方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10188693B2 (enExample) |
| EP (6) | EP2879688A4 (enExample) |
| JP (5) | JP2015524439A (enExample) |
| CN (3) | CN110090304A (enExample) |
| AU (4) | AU2013296493B2 (enExample) |
| CA (2) | CA2880648A1 (enExample) |
| HK (2) | HK1210962A1 (enExample) |
| WO (2) | WO2014022552A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2858550A1 (en) * | 2011-12-09 | 2013-06-13 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| US10188693B2 (en) * | 2012-08-02 | 2019-01-29 | Stealth Biotherapeutics Corp | Methods for treatment of atherosclerosis |
| EP4397314B1 (en) * | 2012-10-22 | 2025-12-03 | Stealth BioTherapeutics Inc. | Treatment of left ventricular remodeling |
| WO2015183984A2 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including tocopherol and uses thereof |
| WO2015183985A2 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including naphthoquinones and uses thereof |
| WO2015183970A1 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including flavonoid and uses thereof |
| RU2623876C2 (ru) * | 2014-11-10 | 2017-06-29 | Александр Владимирович Диковский | Фармацевтическая композиция для лечения гиперлипидемии |
| WO2016190852A1 (en) * | 2015-05-26 | 2016-12-01 | Stealth Peptides International, Inc. | Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof |
| US20180318381A1 (en) * | 2015-10-23 | 2018-11-08 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Methods of Treatment of Rhabdomyolysis |
| US11355245B2 (en) * | 2016-05-03 | 2022-06-07 | International Business Machines Corporation | Identifying and ranking risk factors using trained predictive models |
| ES2871783T3 (es) * | 2016-09-20 | 2021-11-02 | Univ Aarhus | Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas |
| CN107041946A (zh) * | 2017-03-24 | 2017-08-15 | 南京大学 | 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用 |
| US11034724B2 (en) | 2017-04-05 | 2021-06-15 | Stealth Biotherapeutics Corp. | Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2 |
| US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| GB202005439D0 (en) | 2020-04-14 | 2020-05-27 | Aurigen Medical Ltd | A device for occlusion of a left a trial appendage of a heart |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4489710A (en) | 1981-06-23 | 1984-12-25 | Xoma Corporation | Composition and method for transplantation therapy |
| US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4625014A (en) | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| AU2002336959B2 (en) | 2001-08-10 | 2006-07-13 | Novartis Ag | Peptides that bind to atherosclerotic lesions |
| SI2656854T1 (sl) * | 2003-02-04 | 2015-09-30 | Cornell Research Foundation, Inc. | Uporabe aromatsko-kationskega peptida |
| EP3167935B1 (en) * | 2003-05-01 | 2018-07-18 | Cornell Research Foundation, Inc. | Method and carrier complexes for delivering molecules to cells |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| HUE035853T2 (en) | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| EP3725324A1 (en) * | 2005-09-16 | 2020-10-21 | Cornell Research Foundation, Inc. | Aromatic-cationic peptide for use in a method for reducing cd36 expression |
| CA2640615A1 (en) * | 2006-01-30 | 2007-08-09 | Israel Ben David Bryson | Compositions and methods for treating cardiovascular, cerebrovascular and other vascular disease patients |
| WO2008026702A1 (fr) | 2006-08-30 | 2008-03-06 | Kyushu University, National University Corporation | Composition pharmaceutique contenant une nanoparticule de statine encapsulée |
| WO2009092073A2 (en) * | 2008-01-18 | 2009-07-23 | Shire Llc | Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects |
| EP2712620A1 (en) * | 2008-02-07 | 2014-04-02 | Cornell University | Methods for Preventing or Treating Insulin Resistance |
| CA2770688C (en) | 2009-08-12 | 2018-06-05 | Cornell University | Methods for preventing or treating metabolic syndrome |
| SI3708178T1 (sl) * | 2009-08-24 | 2024-01-31 | Stealth Biotherapeutics Inc. | Peptid za uporabo pri preprečevanju ali zdravljenju degeneracije makule |
| EP3332795A1 (en) * | 2010-02-26 | 2018-06-13 | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
| EP2808029A3 (en) | 2010-03-15 | 2015-04-01 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| CN103261230A (zh) * | 2010-12-22 | 2013-08-21 | 霍夫曼-拉罗奇有限公司 | 抗pcsk9抗体及使用方法 |
| US10188693B2 (en) * | 2012-08-02 | 2019-01-29 | Stealth Biotherapeutics Corp | Methods for treatment of atherosclerosis |
-
2013
- 2013-07-31 US US14/418,827 patent/US10188693B2/en active Active
- 2013-07-31 EP EP13824883.6A patent/EP2879688A4/en not_active Withdrawn
- 2013-07-31 EP EP16174236.6A patent/EP3132800A1/en not_active Withdrawn
- 2013-07-31 HK HK15111866.1A patent/HK1210962A1/xx unknown
- 2013-07-31 WO PCT/US2013/053008 patent/WO2014022552A1/en not_active Ceased
- 2013-07-31 CN CN201910002871.XA patent/CN110090304A/zh active Pending
- 2013-07-31 HK HK15111769.9A patent/HK1210953A1/xx unknown
- 2013-07-31 EP EP19209275.7A patent/EP3662921A1/en not_active Withdrawn
- 2013-07-31 CN CN201380049762.4A patent/CN104768564A/zh active Pending
- 2013-07-31 EP EP18198495.6A patent/EP3485897A1/en not_active Withdrawn
- 2013-07-31 EP EP13825389.3A patent/EP2879689A4/en not_active Withdrawn
- 2013-07-31 CN CN201380049785.5A patent/CN104661670A/zh active Pending
- 2013-07-31 AU AU2013296493A patent/AU2013296493B2/en active Active
- 2013-07-31 CA CA2880648A patent/CA2880648A1/en not_active Abandoned
- 2013-07-31 WO PCT/US2013/053007 patent/WO2014022551A1/en not_active Ceased
- 2013-07-31 JP JP2015525555A patent/JP2015524439A/ja active Pending
- 2013-07-31 US US14/418,809 patent/US10201585B2/en active Active
- 2013-07-31 JP JP2015525554A patent/JP2015529655A/ja active Pending
- 2013-07-31 AU AU2013296494A patent/AU2013296494B2/en active Active
- 2013-07-31 EP EP17186931.6A patent/EP3300740A1/en not_active Withdrawn
- 2013-07-31 CA CA2880643A patent/CA2880643A1/en not_active Abandoned
-
2017
- 2017-10-04 JP JP2017194137A patent/JP2018016637A/ja active Pending
- 2017-10-06 JP JP2017195835A patent/JP2018012726A/ja active Pending
- 2017-12-20 US US15/848,198 patent/US20180344797A1/en not_active Abandoned
- 2017-12-20 US US15/848,712 patent/US20180339012A1/en not_active Abandoned
-
2018
- 2018-03-23 AU AU2018202068A patent/AU2018202068A1/en not_active Abandoned
- 2018-03-27 AU AU2018202197A patent/AU2018202197A1/en not_active Abandoned
-
2019
- 2019-02-08 US US16/271,185 patent/US20200000870A1/en not_active Abandoned
- 2019-03-08 JP JP2019042213A patent/JP2019108389A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524439A5 (enExample) | ||
| Barter et al. | Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia | |
| AU2013296493B2 (en) | Methods for treatment of atherosclerosis | |
| JP2018508551A5 (ja) | 心血管疾患を処置するか又は心血管疾患のリスクを低減させるためのｅｔｃ１００２及び１種以上のスタチンを含む固定用量組合せ物 | |
| Marcus et al. | Alternate-day dosing with statins | |
| Trentman et al. | Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians | |
| Basile et al. | Overcoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapy | |
| Stein | Management of dyslipidemia in the high-risk patient | |
| Markel | Statins and peripheral arterial disease | |
| Pflieger et al. | Medical management of stable coronary artery disease | |
| JP2010505866A5 (enExample) | ||
| EP1945205A2 (en) | Methods and compositions for treating disorders associated with hyperlipidemia in a mammal | |
| Woo et al. | Comparison of the efficacy and safety of atorvastatin 40 mg/ω-3 fatty acids 4 g fixed-dose combination and atorvastatin 40 mg monotherapy in hypertriglyceridemic patients who poorly respond to atorvastatin 40 mg monotherapy: an 8-week, multicenter, randomized, double-blind Phase III Study | |
| Ho et al. | Statins and their interactions with other lipid-modifying medications: safety issues in the elderly | |
| Lin et al. | The effect of Ezetimibe and Simvastatin Combination Therapy on percutaneous coronary intervention patients | |
| Katsiki et al. | Exploring the management of statin intolerant patients: 2016 and beyond | |
| JP6207560B2 (ja) | 膵炎を治療するためのゲムカベンおよび誘導体 | |
| Castaldo | A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients | |
| JP2008513379A5 (enExample) | ||
| Quarta et al. | Safety and efficacy of ezetimibe with low doses of simvastatin in heart transplant recipients | |
| NZ807894B2 (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| Yusuf et al. | The Indian Polycap Study (TIPS)–Authors' reply | |
| NZ807894A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| Brinton | Newer HMG‐CoA reductase inhibitor (statin) therapies | |
| JP2006176498A5 (enExample) |